Study Findings Provide New Insights Into Lymphoma Therapy

Researchers detail in 'Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma,' new data in lymphoma. "Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD)," scientists in the United States report. "Two hundred and two patients received HDT-ASCT at Memorial Sloan-Kettering Cancer Center for relapsed or refractory HL between December 19...